POTS / Dysautonomia / Orthostatic Intolerance

6. POTS / dysautonomia / orthostatic intolerance

Postural orthostatic tachycardia syndrome (POTS) belongs to the disorders of the autonomic (vegetative) nervous system (dysautonomias) and is part of the group of orthostatic intolerance – that is, symptoms that are triggered by standing upright and improve when lying down. On standing up, those affected experience a pronounced rise in heart rate, often accompanied by palpitations, light-headedness, presyncope (near-fainting), exhaustion, exertion intolerance and difficulty concentrating ("brain fog") [1][4]. Note: recurrent true fainting attacks (syncope) are atypical for POTS; they, as well as new chest pain, racing heart at rest or breathlessness, should be assessed by a doctor to rule out other (among them cardiac) causes.

Definition and diagnostic criteria

POTS is defined by a sustained rise in heart rate of ≥30 beats/minute within the first 10 minutes after standing up, or in the tilt-table test (head-up tilt) – in adults [1][6]. In adolescents (up to ~19 years) a higher threshold of ≥40 beats/minute applies, because young people physiologically respond more strongly with heart rate [4]. Decisive is the distinction from orthostatic hypotension (OH): OH is present with a drop in blood pressure of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes. POTS is by definition without such a sustained drop in blood pressure – such a drop is an exclusion criterion [1][6]. The symptoms must be chronic: the international expert consensus statement (2015) typically requires a duration of ≥6 months; some (especially older or paediatric) definitions use ≥3 months [4].

Diagnostics

For everyday practice, the active stand test or the 10-minute NASA lean test is well suited: after 5–10 minutes of rest lying on the back (stable baseline values with two consistent measurements), the person stands with their shoulder blades against the wall, heels about 15 cm (6 inches) from the wall; pulse and blood pressure are measured every minute over 10 minutes [2][3]. The tilt table (monitored) is often used as a reference method for complex or delayed cases, while the low-threshold active stand test is suited to primary care and to strongly symptomatic patients [2]. Note: whether the tilt table counts as a "gold standard" is professionally disputed – the active stand test reproduces the everyday situation and is often equivalent or sufficient.

Subtypes

POTS is not a uniform disease; four widely accepted, partly overlapping primary subtypes are distinguished – the figures vary from study to study and should not be understood as fixed quantities [1]: - Neuropathic: length-dependent autonomic neuropathy with sympathetic denervation of the legs and venous pooling; a relevant proportion (in some series around ~50 %) shows a peripheral sudomotor (sweat-gland) denervation. - Hyperadrenergic: raised plasma noradrenaline when standing (guide value ≥600 pg/mL), often with tremor, palpitations and in part orthostatic hypertension (proportions in the literature about 30–60 %). - Hypovolaemic: reduced blood and plasma volume, in part with paradoxically low renin/aldosterone. - Autoimmune: often post-viral, female-dominant; autoantibody/ANA findings variable. Deconditioning (among other things reduced left ventricular mass) is, by contrast, not counted as its own primary subtype, but is discussed as a secondary, reinforcing factor that can add to any of the four subtypes and worsen symptoms – not as their cause.

Connection with hypermobility (EDS/HSD) and mast cells

POTS, joint-related hypermobility (hypermobility spectrum, HSD for short, or the more narrowly defined hypermobile Ehlers-Danlos syndrome, hEDS) and mast cell activation syndrome (MCAS) are noticeably often seen together in practice – sometimes called a "triad" in patient and clinical circles. An analysis of 100 young people with POTS (Frontiers in Neurology, 2025) found, depending on the criteria used, 13–34% with joint hypermobility and 2–87% with MCAS – the wide range shows how strongly such figures depend on the case definition used, and they should therefore not be misread as a fixed frequency. A possible mechanism discussed is that mast-cell elastases damage connective tissue in joints/ligaments (a possible contributing cause of hypermobility) while also damaging the gut lining, which via disrupted vagus-nerve function could favour dysautonomia – a plausible but not yet conclusively proven hypothesis. mypacing records hypermobility/EDS as its own entry in the health profile; a diagnosis, however, is always made by medical or specialist staff.

Frequency

The prevalence is roughly estimated at about 0.2 % of the population (on the order of ~0.5–3 million affected people in the USA – the estimates are uncertain); onset is mostly between 15 and 50 years, the ratio of women to men about 4–5:1 [4][6]. Newer, patient-led surveys, however, report a markedly higher female proportion of over 80 %; a possible reason discussed is that POTS is on average diagnosed later, or less often, in men. The true magnitude of the gender ratio therefore remains uncertain.

Basic therapy (non-drug)

The basis of treatment is non-drug measures [1][5]. The following amounts are orientation values and should be adjusted individually and by a doctor: - Fluids: often 2–3 litres/day to increase blood volume [1]; Dysautonomia International names a practical ~2–2.5 L [5]. A very high fluid intake without sufficient sodium intake is not sensible and is potentially harmful in heart/kidney disease. - Salt/sodium: increased intake is recommended – individually and under medical supervision, since contraindications such as heart or kidney disease and high blood pressure may exist [1][5]. Attention, units: sources do not always cleanly distinguish between table salt (NaCl) and sodium (≈10 g salt corresponds to ~4 g sodium); the figures in circulation (e.g. up to ~10 g salt/day or several grams of sodium/day) are therefore not directly comparable and should be checked against the original source. - Compression: compression garments (guide value ~30 mmHg ankle pressure, in part up to 40 mmHg), ideally waist-high (including the abdominal region), reduce venous pooling [5]. - Counter-manoeuvres (crossing the legs, tensing the muscles), raising the head of the bed and reclined/lying training (swimming, rowing, recumbent bike), which should be increased slowly and under guidance [5].

Quick practical check: making sense of a single elevated heart rate reading

One elevated reading now and then is not automatically a worsening — there is often a harmless, temporary reason behind it. Before treating a spike as a symptom, a short check helps: Was medication taken as usual? Was there a meal just before (digestion raises heart rate temporarily)? Is it warm or hot? Was there excitement, stress, or fast, shallow breathing just now? Was something more strenuous done in the last hour? Did the person just stand up or have they been standing for a while (then it is more likely the orthostatic component itself, see above)? If none of that applies and the heart rate stays persistently elevated, or comes with other symptoms such as dizziness, shortness of breath or chest pain — that belongs in medical hands, not self-assessment. This list does not replace diagnostics; it only helps with a first read of a single reading in daily life.

Medications – note

If basic therapy is not enough, different medications are used depending on the subtype (e.g. beta-blockers, ivabradine, fludrocortisone, midodrine, pyridostigmine). Important: most of these substances are not officially approved for POTS and are used off-label; the evidence rests mostly on small studies and expert consensus. Mechanism of action, benefit, side effects and contraindications must be weighed individually by a doctor. This text does not replace medical advice and deliberately gives no dosing recommendations; every drug therapy belongs in specialist hands.

Connection with Long COVID

POTS is described as one possible manifestation of Long COVID. In a highly symptomatic, non-hospitalised cohort, a substantial proportion (in one study ~31 %) were formally diagnosed with POTS [7][10]; in strongly selected groups, according to reports, up to ~79 % of highly symptomatic Long COVID patients met the POTS criteria, and the literature reports autonomic dysfunction in ~30–60 % [8]. One analysis described an approximately 5-fold increased POTS risk after COVID-19 infection compared with after vaccination [9] – with POTS also being rare after vaccination, and markedly rarer than after infection; this is not an argument against vaccination.

Placing the uncertainties: the prevalence, subtype and Long COVID figures vary considerably depending on cohort and investigation method; the Long COVID values named come from strongly selected, highly symptomatic groups and cannot be transferred to all those affected or to the general population. Several individual figures in this section (exact percentages, cohort sizes, quantities) should be verified against the original sources [1]–[10] before being passed on. Diagnosis and therapy should always be carried out individually and with medical guidance.